View Exam | PowerPak

1. Which of the following statements regarding triple-negative breast cancer (TNBC) is incorrect?

A. TNBC is very responsive to chemotherapy B. TNBC has a very high tendency for recurrence C. TNBC is very common in older patients D. TNBC is defined as a disease with high heterogenicity E. Unsure

2. KS is a 48-year-old woman with newly diagnosed triple-negative breast cancer (TNBC). Her disease was considered as stage IV due to small lung nodules that appeared on computed tomography (CT) scan. What other characteristic needs to be known in order for KS to be eligible to receive immunotherapy?

A. Tumor mutational burden (TMB) B. Tumor-infiltrating lymphocyte (TIL) score C. Microsatellite instability (MSI) status of low D. Programmed cell death protein 1 (PD-1) expression E. Unsure

3. Which of the following choices correctly lists the immune checkpoint inhibitor and taxane combination that is approved by the United States Food and Drug Administration (FDA) for triple-negative breast cancer (TNBC)?

A. Atezolizumab + nab-paclitaxel B. Atezolizumab + docetaxel C. Pembrolizumab + paclitaxel D. Pembrolizumab + nab-paclitaxel E. Unsure

4. Which of the following is not a component of the management of immune-mediated adverse events (imAEs)?

A. Early recognition B. Supportive care C. Corticosteroids D. Antiemetics E. Unsure

5. Patients with which of the following comorbidities were eligible for inclusion in clinical trials involving immune checkpoint inhibitor (ICI) monotherapy and combination therapy?

A. Solid organ transplant recipient B. Pregnancy C. Active autoimmune disorder D. Diabetes E. Unsure

Evaluation Questions

6. How confident are in your diagnostic choice for KS in question #2:

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following statements regarding triple-negative breast cancer (TNBC) is incorrect?

3. Which of the following choices correctly lists the immune checkpoint inhibitor and taxane combination that is approved by the United States Food and Drug Administration (FDA) for triple-negative breast cancer (TNBC)?

4. Which of the following is not a component of the management of immune-mediated adverse events (imAEs)?

5. Patients with which of the following comorbidities were eligible for inclusion in clinical trials involving immune checkpoint inhibitor (ICI) monotherapy and combination therapy?

Evaluation Questions

6. How confident are in your diagnostic choice for KS in question #2:

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following statements regarding triple-negative breast cancer (TNBC) is incorrect?

3. Which of the following choices correctly lists the immune checkpoint inhibitor and taxane combination that is approved by the United States Food and Drug Administration (FDA) for triple-negative breast cancer (TNBC)?

4. Which of the following is not a component of the management of immune-mediated adverse events (imAEs)?

5. Patients with which of the following comorbidities were eligible for inclusion in clinical trials involving immune checkpoint inhibitor (ICI) monotherapy and combination therapy?

Evaluation Questions

6. How confident are in your diagnostic choice for KS in question #2:

« Return to Activity

Customers who Purchased
this Activity also Purchased